Close Menu

stock rating

NEW YORK (GenomeWeb News) – Despite healthier than expected spending during the second quarter, life science researchers are expected to tighten their purse strings for the remainder of the year, according to the results of a survey conducted by investment firm Goldman Sachs.

NEW YORK (GenomeWeb News) – Investment bank Credit Suisse today upgraded Illumina's stock, citing the firm's improved financial performance over the past two quarters and the potential of its tools for the clinical market in the longer term.

NEW YORK (GenomeWeb News) – Investment bank Goldman Sachs has reinstated coverage of Illumina, giving it a Neutral rating and a 12-month price target on its stock of $48.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Citigroup upgraded Life Technologies to Buy today following last week's contraction in the company's stock price.

By a GenomeWeb staff reporter NEW YORK (GenomeWeb News) – Investment bank Leerink Swann today upgraded Life Technologies to Outperform, noting the potential growth of the company's next-generation sequencing business.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Citing expected organic growth and a continuing ramp up of QIAsymphony, investment bank JP Morgan today upgraded Qiagen to Overweight.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Deutsche Bank has initiated coverage of Gen-Probe with a Buy rating and a $70.50 price target.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Goldman Sachs today upgraded PerkinElmer and Affymetrix but downgraded Thermo Fisher Scientific.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Investment firm Credit Suisse has initiated coverage of six companies operating in the life science tools and molecular diagnostics space.

Pages

Nature News reports on how meeting cancellations and related costs are affecting scientific societies.

In a new ruling, Canada's Supreme Court upheld the country's genetic non-discrimination law, the Canadian Press reports.

COVID-19 vaccine developers aim to avoid a complication that has affected efforts to develop vaccines for other diseases, the Wall Street Journal reports.

In PLOS this week: analysis of insertions throughout Shigella genomes, antigen production in malaria parasites, and more.